BioCentury
ARTICLE | Company News

Alteon, BioRap Technologies Ltd., Oxis deal

April 16, 2007 7:00 AM UTC

ALT and BioRap expanded a 2005 deal to give ALT rights to all BioRap’s cardiovascular diagnostic technologies. BioRap will receive an upfront payment and research funding and is eligible for milestones and royalties. The original deal included rights to a haptoglobin blood test and a related therapeutic to treat vascular complications and restenosis in Type II diabetes patients (see BioCentury, May 30, 2005). ALT gained those rights through its acquisition of HaptoGuard Inc. (see BioCentury, April 24, 2006). BioRap is the commercialization arm of Technion University’s Rappaport Family Institute for Research.

Separately, ALT and OXIS expanded a 2004 deal to give ALT exclusive, worldwide rights to develop, manufacture and market ALT-2074 (formerly BXT-51072) and related organoselenium compounds for all indications. The original deal included cardiovascular indications (see BioCentury, October 4, 2004). The partners also eliminated OXIS’s exclusive right to supply the compounds to ALT. ...